Saturday, March 21, 2015 10:31:21 PM
I think it is the opposite. The fact that Merck obviously hands out Keytruda to anyone willing to try a combination trial negates the notion that ONCS is somehow special just because Pierce used to work for Merck. ONCS may have a good hypothesis for combining Immunopulse with Keytruda (I like that hypothesis as well or else I would not be invested/interested in this stock), but make no mistake, that did not make ONCS special to Merck. ONCS still has to prove it works, just like all of the other researchers that Merck has supplied Keytruda to.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM